New Jersey's first private medical school in 50 years is planned for part of the 110-acre Hoffmann-La Roche property. Roche plans to vacate the land in 2015 after an 80-year history in Clifton and Nutley.

Novartis India has agreed to transfer its over-the-counter division (OTC Division) to GlaxoSmithKline Consumer (GSK CPL), a consumer healthcare joint venture (JV) between Swiss pharmaceutical firm Novartis and GSK, for about INR1.097bn ($17.6m)

The cash just keeps flowing in health IT, as does M&A activity.

According to Mercom Capital Group, venture capital in the health IT space reached $4.7 billion in 2014, up from $2.2 billion the year prior. Rock Health recently put the figure at $4 billion, although it’s count does not include deals under $2 million.

FierceBiotech on Wednesday delivered the first big verdict on the “mood” of the JP Morgan Healthcare Conference – based largely on its executive breakfast held this week in San Francisco. The verdict: Real confidence well above and beyond the typical happy face you’d get, regardless, at JP Morgan.

The Johns Hopkins University Applied Physics Laboratory (APL), in Laurel, Maryland, has received $4 million in funding from the Mann Fund to develop a next-generation retinal prosthesis system. The Mann Fund was created by philanthropist Alfred E. Mann 15 years ago to support the development of biomedical technologies.

In the summer of 2013, Pamela Shavaun Scott started having "24/7 severe headaches" — so severe that she couldn't sleep. It wasn't before December that she heard for sure that it was a brain tumor.

Harvard University has long played an outsized role in spurring the growth of the Boston area’s life sciences industry, but the school’s contributions have largely unfolded behind the scenes.

Unlike the Massachusetts Institute of Technology in Cambridge’s Kendall Square — the beating heart of biotech — Harvard has been known less for spinning off startups than for licensing cutting-edge research and grooming the industry’s business leaders.

A trio of scientists have started working with researchers at GlaxoSmitKline on a potential cure for cancer. In fact, they believe they've found the diseases' "Achilles heel."

Last month, GlaxoSmithKline (NYSE: GSK) selected a Wistar/Penn project for its 2014 Discovery Fast Track Challenge program, which was created to accelerate the development of new medicines.

A Exciting Opportunity for Investor Meetings and Showcases

SUBMISSION DEADLINE: January 21, 2015  

We invite you to submit your high-growth and innovative companies to individually meet with and showcase to an exclusive Global 1000 Transaction Network of Corporate Investors, Venture Capitalists, and Angel Investors at the Combined University Startups and Global 1000 Meet | Partner | Deal Conference in Washington, DC, on March 11 and 12, 2015.

The United States shouldn’t worry just yet about losing the number one spot as far as disease-related research in the world goes – that’s pretty solid – but that doesn’t mean the country is steadily moving forward the way it could or should.

‘Tis the season for dieting and purchasing gym memberships you may or may not use.

There are plenty of tactics out there for how to drop excess weight fast, and generally speaking, most of them probably won’t be the quick fix resolutionaries are hoping for (yes, that’s a made up word).

In 2012, we authored a report titled The Evolving Business Case for Social Media in Healthcare – a publication covering the range of social media influences on the industry.  These influences were essentially cloud-based approaches to sharing information between consumers, individual care professionals and healthcare organizations.

The Colonial Room of the St. Francis Hotel in San Francisco was filled beyond capacity Monday afternoon, and the offices of digital-health seed fund Rock Health were buzzing with hundreds of partygoers just a couple of hours later.

Swiss drugmaker Roche said on Wednesday it had entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents, pertaining to the detection of mutations in the EGFR pathway.

In a laboratory first, Duke researchers have grown human skeletal muscle that contracts and responds just like native tissue to external stimuli such as electrical pulses, biochemical signals and pharmaceuticals.

It didn't take R. Michael Gill very long to come up with some priorities after Gov.-elect Larry Hogan named him the next Maryland Department of Business and Economic Development secretary last week.

Gill wants to keep McCormick & Co. Inc. (NYSE: MKC) in state. He wants to bring the FBI headquarters to Maryland. And he wants to emphasize customer service in dealing with businesses.

Lockheed Martin Corp. is normally known for big things – tanks, planes, ships, those kinds of projects.

But a new partnership the defense giant has formed with a San Diego company has Lockheed looking at something very, very small.

The ETC (Emerging Technology Centers) www.etcbaltimore.com, Baltimore City’s award-winning technology innovation centers, announced today that the following six companies have been accepted into the AccelerateBaltimore™ 2015 program:

Show me the money, I'm not seeing it here.

According to NVCA, U.S. VC firms raised $29.8B in 2014, making it the best fundraising year since 2007 ('13 was $17.7B). Overall this is good news, but there has not been local traction. Here is the data from NVCA on the D.C. located funds that raised capital in '14:

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis' lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV). The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.

Washington, D.C., Philadelphia, New York — Maryland has a lot of competition for entrepreneurs' attention. Experts say a tax credit specifically for angel investors could sweeten the deal for entrepreneurs and investors who decide to do business in Maryland.

Establishing an angel investor tax credit will be a top priority for the Greater Baltimore Committee during the state's upcoming legislative session. GBC sees the tax credit as a way to boost the state's economy by supporting growing startups that will create jobs and bring new business to Maryland. Investors and adivsors of Baltimore-area startups say the tax credit would not only help startups grow in Maryland, but keep them — and their investors — from laying roots elsewhere.

Sample and assay technologies provider Qiagen NV recently announced the launch of its latest diagnostic TB test– QuantiFERON-TB Gold-Plus (QFT-Plus), subsequent to the product’s receipt of CE Mark in Europe.

QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection. It involves Qiagen’s proprietary QuantiFERON technology which can uniquely identify presymptomatic infections that standard diagnostic technologies fail to detect.

Alexandria Real Estate Equities, the real estate firm that helped transform Mission Bay into a thriving life-science hub, now wants to raise up to $20 million to build digital-health companies from scratch in San Francisco.

Alexandria, the nation’s largest owner and developer of real estate for the life-science industry, said in August that it would start three new accelerators nationwide to support startups in biotech, agriculture and digital health. The biotech space is up and running in New York City with $51 million in financing, and the agriculture space is expected to open within the next six months in North Carolina.

J. Craig Venter was one of the first scientists in 2001 to map the human genome. Now this trailblazer in genome sequencing research has his sights set on creating the world's largest database of human genomes. And he's calling in Baltimore startup Personal Genome Diagnostics Inc. to help.

BD Medical, a part of Becton, Dickinson and Company, announced receiving FDA clearance for its Intelliport Medication Management System. The product monitors manual IV bolus injections, automatically records how much of which medication a patient receives and warns of allergies by interfacing with the hospital’s electronic medical records.

The Beyond the Pill movement took an interesting turn this week when Qualcomm announced plans to open an investment business with Novartis, according to a company statement. Qualcomm will launch the investment company through its Qualcomm Ventures business. The news splash at the start of the JP Morgan Healthcare conference came about a week after the two companies said at the International CES in Las Vegas that they would collaborate on digital health as part of Novartis’ Trials of the Future program.

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV). The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.

Qiagen announced on Sunday that it has acquired the enzyme solutions unit of Enzymatics, a supplier of enzymes used in next-generation sequencing and other genetic analysis technologies in life sciences research and clinical applications, for an undisclosed amount.

The Swiss pharmaceutical giant Roche said on Monday that it would acquire a majority stake in the tumor-testing company Foundation Medicine for more than $1 billion, in a deal aimed at improving both cancer treatment and drug development.

Foundation is the leader in the growing area of sequencing the genes of tumor samples, looking for mutations that can help predict which drug will be most effective for a particular patient.

Roche, the world’s largest maker of cancer drugs, is spending $1.03 billion to buy a 56.3% stake in Cambridge, Mass.-based Foundation Medicine, a company that uses genetics to help select drugs for cancer patients. Roche, based in Basel, Switzerland, will also market Foundation’s diagnostic tests outside the U.S., help educate doctors as to the value of the tests in the U.S., and provide another $150 million to support additional research on Foundation’s products.

The most significant announcement that Apple made in 2014 wasn’t a larger-sized iPhone. It was that Apple is entering the health-care industry. With HealthKit, it is building an iTunes-like platform for health; Apple Watch is its first medical device. Apple is, however, two steps behind Google, IBM and hundreds of startups. They realized much earlier that medicine is becoming an information technology and that the trillion-dollar health-care market is ripe for disruption.

The Tech Council of Maryland plans to outline its legislative priorities Monday as state lawmakers head to Annapolis next week, but lobbyists will have to contend with a new governor and constrained budget as they push their agenda.

Balitmore's PathSensors Inc. has received $500,000 from a Chinese investor to expand the bioscience company's footprint in China.

The private investor, Michael Song, is president of Shanghai Qi Fa Electronics Co. Ltd. in China. The money will allow PathSensors to grow sales of its surface and airborne detection systems in China. Funding will also go toward market expansion in the U.S.

Greater Baltimore Committee wants legislators to establish a state tax credit for angel investors who support early-stage companies.

Legislation to create the tax credit will be a top priority for the business advocacy group during the upcoming General Assembly session. The organization will also push for programs to create more on-the-job training opportunities for students. Priorities also include strengthening science and technology education in grade school and securing funding for transportation infrastructure.